DOCSLIB.ORG

Pharmaceuticals Appendix

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceuticals Appendix )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1 ALACEPRIL 74258-86-9 ACEFYLLINE PIPERAZINE 18428-63-2 ALAFOSFALIN 60668-24-8 ACEGLATONE 642-83-1 ALANINE 56-41-7 ACEGLUTAMIDE 2490-97-3 ALANOSINE 5854-93-3 ACEMANNAN 110042-95-0 ALAPROCLATE 60719-82-6 ACEMETACIN 53164-05-9 ALAZANINE TRICLOFENATE 5779-59-9 ACENEURAMIC ACID 131-48-6 ALBENDAZOLE 54965-21-8 ACENOCOUMAROL 152-72-7 ALBENDAZOLE OXIDE 54029-12-8 ACEPERONE 807-31-8 ALBIFYLLINE 107767-55-5 ACEPROMAZINE 61-00-7 ALBUTOIN 830-89-7 ACEPROMETAZINE 13461-01-3 ALCLOFENAC 22131-79-9 ACEQUINOLINE 42465-20-3 ALCLOMETASONE 67452-97-5 ACESULFAME 33665-90-6 ALCLOXA 1317-25-5 ACETAMINOSALOL 118-57-0 ALCURONIUM CHLORIDE 15180-03-7 ACETARSOL 97-44-9 ALDESULFONE SODIUM 144-75-2 ACETAZOLAMIDE 59-66-5 ALDIOXA 5579-81-7 ACETERGAMINE 3031-48-9 ALDOSTERONE 52-39-1 ACETIAMINE 299-89-8 ALENDRONIC ACID 66376-36-1 ACETIROMATE 2260-08-4 ALENTEMOL 112891-97-1 ACETOHEXAMIDE 968-81-0 ALEPRIDE 66564-15-6 ACETOHYDROXAMIC ACID 546-88-3 ALESTRAMUSTINE 139402-18-9 ACETOPHENAZINE 2751-68-0 ALEXIDINE 22573-93-9 ACETORPHINE 25333-77-1 ALEXITOL SODIUM 66813-51-2 ACETRYPTINE 3551-18-6 ALFACALCIDOL 41294-56-8 ACETYLCHOLINE CHLORIDE 60-31-1 ALFADEX 10016-20-3 ACETYLCYSTEINE 616-91-1 ALFADOLONE 14107-37-0 ACETYLDIGITOXIN 1111-39-3 ALFAPROSTOL 74176-31-1 ACETYLLEUCINE 99-15-0 ALFAXALONE 23930-19-0 ACETYLMETHADOL 509-74-0 ALFENTANIL 71195-58-9 ACEVALTRATE 25161-41-5 ALFETAMINE 4255-23-6 ACEXAMIC ACID 57-08-9 ALFUZOSIN 81403-80-7 ACICLOVIR 59277-89-3 ALGELDRATE 1330-44-5 ACIFRAN 72420-38-3 ALGESTONE 595-77-7 ACIPIMOX 51037-30-0 ALGLUCERASE 143003-46-7 ACITEMATE 101197-99-3 ALIBENDOL 26750-81-2 ACITRETIN 55079-83-9 ALICONAZOLE 63824-12-4 ACIVICIN 42228-92-2 ALIFEDRINE 78756-61-3 ACLANTATE 39633-62-0 ALIFLURANE 56689-41-9 ACLARUBICIN 57576-44-0 ALIMADOL 52742-40-2 ACLATONIUM NAPADISILATE 55077-30-0 ALIMEMAZINE 84-96-8 ACODAZOLE 79152-85-5 ALINIDINE 33178-86-8 ACONIAZIDE 13410-86-1 ALIPAMIDE 3184-59-6 ACOXATRINE 748-44-7 ALIZAPRIDE 59338-93-1 ACRIDOREX 47487-22-9 ALLETORPHINE 23758-80-7 ACRIFLAVINIUM CHLORIDE 8063-24-9 ALLOBARBITAL 52-43-7 ACRIHELLIN 67696-82-6 ALLOCLAMIDE 5486-77-1 ACRISORCIN 7527-91-5 ALLOCUPREIDE SODIUM 5965-40-2 ACRIVASTINE 87848-99-5 ALLOMETHADIONE 526-35-2 ACROCINONIDE 28971-58-6 ALLOPURINOL 315-30-0 ACRONINE 7008-42-6 ALLYLESTRENOL 432-60-0 ACTAGARDIN ALLYLPRODINE 25384-17-2 ACTAPLANIN 37305-75-2 ALLYLTHIOUREA 109-57-9 ACTARIT 18699-02-0 ALMADRATE SULFATE 60239-66-9 ACTINOQUINOL 15301-40-3 ALMAGATE 66827-12-1 ACTISOMIDE 96914-39-5 ALMASILATE 71205-22-6 ACTODIGIN 36983-69-4 ALMECILLIN 87-09-2 ADAFENOXATE 82168-26-1 ALMESTRONE 10448-96-1 ADAMEXINE 54785-02-3 ALMINOPROFEN 39718-89-3 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 4 Table 1 (con.) Product CAS Number Product CAS Number ALMITRINE 27469-53-0 AMIKHELLINE 4439-67-2 ALMOKALANT 123955-10-2 AMILORIDE 2609-46-3 ALMOXATONE 84145-89-1 AMINDOCATE 31386-24-0 ALONACIC 105292-70-4 AMINEPTINE 57574-09-1 ALONIMID 2897-83-8 AMINITROZOLE 140-40-9 ALORACETAM 119610-26-3 AMINOACRIDINE 90-45-9 ALOSETRON 122852-42-0 AMINOCAPROIC ACID 60-32-2 ALOVUDINE 25526-93-6 AMINOETHYL NITRATE 646-02-6 ALOXIPRIN 9014-67-9 AMINOGLUTETHIMIDE 125-84-8 ALOXISTATIN 88321-09-9 AMINOMETRADINE 642-44-4 ALOZAFONE 65899-72-1 AMINOPHENAZONE 58-15-1 ALPERTINE 27076-46-6 AMINOPHENAZONE CYCLAMATE 747-30-8 ALPHACETYLMETHADOL 17199-58-5 AMINOPHYLLINE 317-34-0 ALPHAMEPRODINE 468-51-9 AMINOPROMAZINE 58-37-7 ALPHAMETHADOL 17199-54-1 AMINOPTERIN SODIUM 58602-66-7 ALPHAPRODINE 77-20-3 AMINOQUINOL 10023-54-8 ALPIDEM 82626-01-5 AMINOQUINURIDE 3811-56-1 ALPIROPRIDE 81982-32-3 AMINOREX 2207-50-3 ALPRAFENONE 124316-02-5 AMINOTHIAZOLE 96-50-4 ALPRAZOLAM 28981-97-7 AMINOXYTRIPHENE 5585-64-8 ALPRENOLOL 13655-52-2 AMIODARONE 1951-25-3 ALPROSTADIL 745-65-3 AMIPERONE 1580-71-8 ALRESTATIN 51411-04-2 AMIPHENAZOLE 490-55-1 ALSACTIDE 34765-96-3 AMIPIZONE 69635-63-8 ALTANSERIN 76330-71-7 AMIPRILOSE 56824-20-5 ALTAPIZONE 93277-96-4 AMIQUINSIN 13425-92-8 ALTECONAZOLE 93479-96-0 AMISOMETRADINE 550-28-7 ALTEPLASE 105857-23-6 AMISULPRIDE 71675-85-9 ALTIZIDE 5588-16-9 AMITEROL 54063-25-1 ALTOQUALINE 121029-11-6 AMITIVIR 111393-84-1 ALTRENOGEST 850-52-2 AMITRAZ 33089-61-1 ALTRETAMINE 645-05-6 AMITRIPTYLINE 50-48-6 ALTUMOMAB 156586-92-4 AMITRIPTYLINOXIDE 4317-14-0 ALUMINIUM CLOFIBRATE 24818-79-9 AMIXETRINE 24622-72-8 ALUSULF 61115-28-4 AMLEXANOX 68302-57-8 ALVERINE 150-59-4 AMLODIPINE 88150-42-9 ALVIRCEPT SUDOTOX 137487-62-8 AMOBARBITAL 57-43-2 AMADINONE 30781-27-2 AMOCARZINE 36590-19-9 AMAFOLONE 50588-47-1 AMODIAQUINE 86-42-0 AMANOZINE 537-17-7 AMOGASTRIN 16870-37-4 AMANTADINE 768-94-5 AMOLANONE 76-65-3 AMANTANIUM BROMIDE 58158-77-3 AMONAFIDE 69408-81-7 AMANTOCILLIN 10004-67-8 AMOPROXAN 22661-76-3 AMBAMUSTINE 85754-59-2 AMOPYROQUINE 550-81-2 AMBASILIDE 83991-25-7 AMOROLFINE 78613-35-1 AMBAZONE 539-21-9 AMOSCANATE 26328-53-0 AMBENONIUM CHLORIDE 115-79-7 AMOSULALOL 85320-68-9 AMBENOXAN 2455-84-7 AMOXAPINE 14028-44-5 AMBICROMIL 58805-38-2 AMOXECAINE 553-65-1 AMBOMYCIN 1402-81-9 AMOXICILLIN 26787-78-0 AMBROXOL 18683-91-5 AMOXYDRAMINE CAMSILATE 15350-99-9 AMBRUTICIN 58857-02-6 AMPEROZIDE 75558-90-6 AMBUCAINE 119-29-9 AMPHENIDONE 134-37-2 AMBUCETAMIDE 519-88-0 AMPHOTALIDE 1673-06-9 AMBUSIDE 3754-19-6 AMPHOTERICIN B 1397-89-3 AMCINAFAL 3924-70-7 AMPICILLIN 69-53-4 AMCINAFIDE 7332-27-6 AMPIROXICAM 99464-64-9 AMCINONIDE 51022-69-6 AMPROLIUM 121-25-5 AMEBUCORT 83625-35-8 AMPYRIMINE 5587-93-9 AMEDALIN 22136-26-1 AMPYZINE 5214-29-9 AMELTOLIDE 787-93-9 AMQUINATE 17230-85-2 AMESERGIDE 121588-75-8 AMRINONE 60719-84-8 AMETANTRONE 64862-96-0 AMRUBICIN 110267-81-7 AMEZEPINE 60575-32-8 AMSACRINE 51264-14-3 AMEZINIUM METILSULFATE 30578-37-1 AMTOLMETIN GUACIL 87344-06-7 AMFEBUTAMONE 34911-55-2 AMYLMETACRESOL 1300-94-3 AMFECLORAL 5581-35-1 ANAGESTONE 2740-52-5 AMFENAC 51579-82-9 ANAGRELIDE 68475-42-3 AMFEPENTOREX 15686-27-8 ANARITIDE 95896-08-5 AMFEPRAMONE 90-84-6 ANAXIRONE 77658-97-0 AMFETAMINE 300-62-9 ANAZOCINE 15378-99-1 AMFETAMINIL 17590-01-1 ANAZOLENE SODIUM 3861-73-2 AMFLUTIZOLE 82114-19-0 ANCAROLOL 75748-50-4 AMFOMYCIN 1402-82-0 ANCITABINE 31698-14-3 AMFONELIC ACID 15180-02-6 ANCROD 9046-56-4 AMICARBALIDE 3459-96-9 ANDOLAST 132640-22-3 AMICIBONE 23271-63-8 ANDROSTANOLONE 521-18-6 AMICYCLINE 5874-95-3 ANGIOTENSINAMIDE 53-73-6 AMIDANTEL 49745-00-8 ANGIOTENSIN II 4474-91-3 AMIDAPSONE 3569-77-5 ANIDOXIME 34297-34-2 AMIDEFRINE MESILATE 1421-68-7 ANILAMATE 5591-49-1 AMIFLAMINE 77518-07-1 ANILERIDINE 144-14-9 AMIFLOVERINE 54063-24-0 ANILOPAM 53716-46-4 AMIFLOXACIN 86393-37-5 ANIPAMIL 83200-10-6 AMIFOSTINE 20537-88-6 ANIRACETAM 72432-10-1 AMIKACIN 37517-28-5 ANIROLAC 66635-85-6 )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 5 Table 1 (con.) ProductCAS Number Product CAS Number ANISACRIL 5129-14-6 AVIZAFONE 65617-86-9 ANISINDIONE 117-37-3 AVOBENZONE 70356-09-1 ANISOPIROL 442-03-5 AVOPARCIN 37332-99-3 ANISTREPLASE 81669-57-0 AVRIDINE 35607-20-6 ANITRAZAFEN 63119-27-7 AXAMOZIDE 85076-06-8 ANPIRTOLINE 98330-05-3 AZABON 1150-20-5 ANSOXETINE 79130-64-6 AZABUPERONE 2856-81-7 ANTAFENITE 15301-45-8 AZACITIDINE 320-67-2 ANTAZOLINE 91-75-8 AZACLORZINE 49864-70-2 ANTAZONITE 25422-75-7 AZACONAZOLE 60207-31-0 ANTELMYCIN 1402-84-2 AZACOSTEROL 313-05-3 ANTHIOLIMINE 305-97-5 AZACYCLONOL 115-46-8 ANTIENITE 5029-05-0 AZAFTOZINE 54063-26-2 ANTRAFENINE 55300-29-3 AZALOMYCIN 54182-65-9 ANTRAMYCIN 4803-27-4 AZALOXAN 72822-56-1 APAFANT 105219-56-5 AZAMETHONIUM BROMIDE 306-53-6 APALCILLIN 63469-19-2 AZAMULIN 76530-44-4 APICYCLINE 15599-51-6 AZANATOR 37855-92-8 APOVINCAMINE 4880-92-6 AZANIDAZOLE 62973-76-6 APRACLONIDINE 66711-21-5 AZAPERONE 1649-18-9 APRAMYCIN 37321-09-8 AZAPROCIN 448-34-0 APRIKALIM 92569-65-8 AZAPROPAZONE 13539-59-8 APRINDINE 37640-71-4 AZAQUINZOLE 5234-86-6 APROBARBITAL 77-02-1 AZARIBINE 2169-64-4 APROFENE 3563-01-7 AZASERINE 115-02-6 APROSULATE SODIUM 123072-45-7 AZASETRON 123040-69-7 APROTININ 9004-04-0 AZASPIRIUM CHLORIDE 34959-30-3 APTAZAPINE 71576-40-4 AZASTENE 13074-00-5 APTOCAINE 19281-29-9 AZATADINE 3964-81-6 ARANIDIPINE 86780-90-7 AZATEPA 125-45-1 ARANOTIN 19885-51-9 AZATHIOPRINE 446-86-6 ARAPROFEN 15250-13-2 AZELAIC ACID 123-99-9
Load more

Recommended publications
  • United States Patent [19] [11] Patent Number: 6,149,923 Shirahase Et Al
    US006149923A United States Patent [19] [11] Patent Number: 6,149,923 Shirahase et al. [45] Date of Patent: Nov. 21, 2000 [54] ANTIRHEUMATIC AGENT OTHER PUBLICATIONS [75] Inventors: Hiroaki Shirahase, Nagaokakyo; Yoshimi et al Importance of Hydrolysis of Amino Acid Akihisa Yoshimi, Takatsuki; Fumio Moiety in Water—Soluble Prodrugs of Disodium Cromogly Fukata, Osaka; Hideki Okunishi; Yuta cate for Increased Oral Bioavailability 1992 J. Pharmaco Kobayashi, both of IZumo, all of Japan bio—Dyn 15:339—345. Mori et al Pro—drugs for the Oral Deliver of Disodium [73] Assignee: Kyoto Pharmaceutical Industries, Cromoglycate 1988 Chem. Pharm. Bull. 36:338—344. Ltd., Kyoto, Japan Primary Examiner—Thurman K. Page Appl. N0.: Assistant Examiner—Todd D. Ware 09/202,368 Attorney, Agent, or Firm—Leydig, Voit & Mayer, Ltd. PCT Filed: Jun. 6, 1997 [57] ABSTRACT PCT No.: PCT/JP97/01974 An antirheumatic agent comprising diethyl § 371 Date: Dec. 10, 1998 L-lysylcromoglycate of the following formula § 102(e) Date: Dec. 10, 1998 NH; PCT Pub. No.: WO97/47297 [87] OCOCH(CH2)4NH2 PCT Pub. Date: Dec. 18, 1997 o OCHZCHCHZO o [30] Foreign Application Priority Data Jun. 11, 1996 [JP] Japan .................................. .. 8-149549 [51] Int. Cl.7 .......................... .. A61K 9/00; A61K 31/35; A01N 43/16 H5c2ooc o o cooczns US. Cl. ......................... .. 424/400; 514/825; 514/456 Field of Search ........................... .. 424/400; 514/825, or a nontoxic salt thereof as an active ingredient. This 514/456 compound has an anti-in?ammatory action and immuno modulating action, is absorbed by oral administration to be References Cited delivered efficiently to local sites, and is associated With feWer side effects, so that it serves Well as an antirheumatic U.S.
    [Show full text]
  • Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and Its Application
    Infect Dis Ther (2017) 6:57–67 DOI 10.1007/s40121-016-0144-8 REVIEW Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application Juwon Yim . Leah M. Molloy . Jason G. Newland Received: November 10, 2016 / Published online: December 30, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT infections, CABP caused by penicillin- and ceftriaxone-resistant S. pneumoniae and Ceftaroline is a novel cephalosporin recently resistant Gram-positive infections that fail approved in children for treatment of acute first-line antimicrobial agents. However, bacterial skin and soft tissue infections and limited data are available on tolerability in community-acquired bacterial pneumonia neonates and infants younger than 2 months (CABP) caused by methicillin-resistant of age, and on pharmacokinetic characteristics Staphylococcus aureus, Streptococcus pneumoniae in children with chronic medical conditions and other susceptible bacteria. With a favorable and those with invasive, complicated tolerability profile and efficacy proven in infections. In this review, the microbiological pediatric patients and excellent in vitro profile of ceftaroline, its mechanism of action, activity against resistant Gram-positive and and pharmacokinetic profile will be presented. Gram-negative bacteria, ceftaroline may serve Additionally, clinical evidence for use in as a therapeutic option for polymicrobial pediatric patients and proposed place in therapy is discussed. Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/ 1F47F0601BB3F2DD. Keywords: Antibiotic resistance; Ceftaroline J. Yim (&) fosamil; Children; Methicillin-resistant St. John Hospital and Medical Center, Detroit, MI, Staphylococcus aureus; Streptococcus pneumoniae USA e-mail: [email protected] L.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Did Internet-Purchased Diet Pills Cause Serotonin Syndrome?
    Did Internet-purchased diet pills cause serotonin syndrome? Phentermine also may have increased patient’s neuroleptic malignant syndrome risk s. G, age 28, presents to a tertiary® careDowden hospital Health Media with altered mental status. Six weeks ago she Mstarted taking phentermine, 37.5 mg/d, to lose weight. Her body mass indexCopyright is 24 kg/mFor2 (normal personal range), use only and she obtained the stimulant agent via the Internet. Her family reports Ms. G was very busy in the past week, staying up until 2 AM cleaning. They say she also was irritable with her 5-year-old son. Two days ago, Ms. G complained of fatigue and nausea without emesis. She went to bed early and did not awaken the next morning. Her sister found her in bed, minimally re- DIONISI sponsive to verbal stimuli, and brought her to the hospital. Patients have used phentermine as a weight-reducing IMAGES/SANDRA GETTY agent since the FDA approved this amphetamine-like © compound in 1960.1 Phentermine’s mechanism of ac- tion is thought to involve dopaminergic, noradrenergic, Kyoung Bin Im, MD and serotonergic effects.2 Stimulation of norepineph- Chief resident Internal medicine and psychiatry combined residency program rine (NE) release is its most potent effect, followed Departments of internal medicine and psychiatry by NE reuptake inhibition, stimulation of dopamine Jess G. Fiedorowicz, MD (DA) release, DA reuptake inhibition, stimulation of Associate in psychiatry serotonin (5-HT) release, and 5-HT reuptake inhibition Department of psychiatry (weak).3 Roy J. and Lucille A. Carver College of Medicine Because phentermine could in theory cause serotonin 4 University of Iowa syndrome, its use is contraindicated with monoamine Iowa City oxidase inhibitors (MAOIs) and not recommended with selective serotonin reuptake inhibitors (SSRIs).5 One case report describes an interaction between fl uox- etine and phentermine that appears consistent with se- rotonin syndrome.6 We are aware of no case reports of Current Psychiatry serotonin syndrome caused by phentermine alone.
    [Show full text]
  • New Rules Pertaining to the Banning of Anabolic Steroids in the Western Australian Harness Racing Industry to Be Introduced 1St September 2014
    NEW RULES PERTAINING TO THE BANNING OF ANABOLIC STEROIDS IN THE WESTERN AUSTRALIAN HARNESS RACING INDUSTRY TO BE INTRODUCED 1ST SEPTEMBER 2014 Notice is hereby given that the Board of Racing and Wagering WA have resolved that the RWWA Rules of Harness Racing 2004 be amended. In accordance with section 45 (1) (b) of the Racing and Wagering Western Australia Act 2003 the Board of Racing and Wagering WA on the 10th April 2014 resolved that these amendments be adopted accordingly into the RWWA Rules of Harness Racing. The Harness Racing Board had advised of these amendments and the RWWA Board has determined that these amendments will come into effect on 1st September 2014. The details of the relevant rules pertaining to this ban of anabolic steroids for reference can be found following this advice. There are many implications arising from the introduction of these rules, and to assist trainers and veterinarians to comply with the new rules the following explanatory statement has been prepared. Which steroids are banned under these rules? The new rules ban the use of "anabolic androgenic steroids" in Standardbred horses at any time from birth until retirement. "Anabolic androgenic steroids" include those that are currently registered in Australia by the APVMA for use in horses, such as boldenone, ethylestrenol (in Nitrotain), methandriol, nandrolone, stanozolol and testosterone. Exogenous anabolic androgenic steroids that are banned also include but are not limited to those listed in the WADA prohibited list, such as 1-androstenediol; 1-androstenedione;
    [Show full text]
  • Adverse Drug Reactions Sample Chapter
    Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Amfepramone (Diethylpropion) Elisa Kit Instructions Product #182119, 182116 & 182113 Forensic Use Only
    Neogen Corporation 944 Nandino Blvd., Lexington KY 40511 USA 800/477-8201 USA/Canada | 859/254-1221 Fax: 859/255-5532 | E-mail: [email protected] | Web: www.neogen.com/Toxicology AMFEPRAMONE (DIETHYLPROPION) ELISA KIT INSTRUCTIONS PRODUCT #182119, 182116 & 182113 FORENSIC USE ONLY INTENDED USE: For the determination of trace quantities of Amfepramone (Diethylpropion) and/or other metabolites in human samples. DESCRIPTION Neogen Corporation’s Amfepramone (Diethylpropion) ELISA (Enzyme-Linked Immunosorbent Assay) test kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for forensic use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS). ASSAY PRINCIPLE The Neogen forensic drug detection ELISA is a solid phase immunoassay designed to detect drugs of abuse for forensic application. The test is performed in microwells coated with a high affinity capture antibody. A control or sample is added to the wells followed by an enzyme conjugate. During the following incubation period, the enzyme conjugate competes with the drug in the sample for binding sites on the antibody coated well. After a wash step to remove any unbound material, substrate is added for the color development process. Acid stop solution is added to discontinue the enzyme-substrate reaction. The color intensity is inversely proportional to the amount of drug present in the sample. Therefore, those samples which contain the drug will inhibit binding of the enzyme conjugate to the capture antibody resulting in less color than the negative control.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]